摘要
目的观察替罗非班对冠状动脉介入治疗患者血液流变学的影响。方法将2009年12月至2011年12月在我院行冠状动脉介入治疗的130例患者随机分为治疗组和对照组,每组65例。冠状动脉介入治疗后,对照组常规口服阿司匹林100 mg/d,氯吡格雷75mg/d,辛伐他汀10mg/d。治疗组冠状动脉内给予替罗非班(杭州中美华东制药有限公司)10μg/(kg min)的负荷量,随后0.15μg/(kg min)持续静脉点滴至术后24 h,之后行常规治疗。治疗前及治疗后1个月检测两组血液流变学指标(包括红细胞比容、血浆黏度、全血黏度高切、全血黏度低切、红细胞聚集指数、纤维蛋白原)。结果治疗后,两组患者血液流变学指标较治疗前均下降(P<0.05);且治疗组在血浆黏度、全血黏度高切、全血黏度低切、红细胞聚集指数、纤维蛋白原等指标上与对照组相比显著降低(P<0.05)。结论常规治疗基础上联合替罗非班可改善患者血液流变学异常,对于PCI术后再狭窄及炎症的预防起到一定的作用,取得较好的临床效果,值得推广应用。
Objective To observe the tirofiban coronary intervention treatment hemorheology in patients.Methods 130 patients underwent coronary intervention treated patients were randomly divided into a treatment group and the control group,65 cases in each group.Coronary intervention control group,the conventional oral aspirin 100 mg/d,clopidogrel 75mg/d,of Simvastatin 10mg/d.Given in the treatment group coronary behalf of the loading dose of tirofiban（Hangzhou,China-US East China Pharmaceutical Co.,Ltd.） 10μg /（kg min）,followed by 0.15 μg/（kg min） continuous infusion to postoperative 24 h after row conventional therapy.One month before treatment and after treatment were detected hemorheology（including hematocrit,plasma viscosity,whole blood viscosity at high shear and low-cut,whole blood viscosity,erythrocyte aggregation,fibrinogen）.Results After treatment,the two groups of patients hemorheology than before treatment decreased（P0.05）;treatment group in plasma viscosity,whole blood viscosity at high shear and low-cut,whole blood viscosity,erythrocyte aggregation,fibrinogenother indicators significantly reduced compared with the control group（P0.05）.Conclusion The conventional treatment on the basis of joint tirofiban can improve hemorheological abnormality in patients with restenosis after PCI and play a role in the prevention of inflammation,achieve better clinical effect,should be widely applied.
出处
《中国医药指南》
2012年第36期48-48,322,共2页
Guide of China Medicine
